<DOC>
	<DOCNO>NCT00157014</DOCNO>
	<brief_summary>The purpose study assess safety efficacy tacrolimus de novo heart transplantation .</brief_summary>
	<brief_title>Canadian Cardiology de Novo Study : A Comparison Between Tacrolimus- Cyclosporine- Based Immunoprophylactic Regimens</brief_title>
	<detailed_description>Subcellular marker assess relationship cellular acute rejection de novo cardiac transplant recipient receive either tacrolimus cyclosporine primary immunosuppressant Two parallel active arm .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients ( legal guardian ) capable understanding , fully inform purpose study risk participation . Patients ( legal guardian ) sign date Informed Consent form willing able follow study protocol . Patients primary cadaveric heart transplant recipient . Males females birth . Female patient childbearing potential current negative pregnancy test agree practice effective birth control , judge investigator , participate study . Prepubescent pediatric patient require pregnancy test . Patients able tolerate oral medication gastrointestinal condition likely affect absorption kinetics metabolism oral study medication . Previous organ transplant recipient . Multiorgan transplant recipient . Recipients heart donor incompatible ABO blood type . Patients significant graft dysfunction and/or significant de novo infection ( ) time randomization Patients know hypersensitivity tacrolimus , cyclosporine , mycophenolate mofetil ( MMF ) , daclizumab , prednisone , cremophor , polysorbate 80 and/or polyoxyl 60 hydrogenate castor oil ( HCO60 ) . Patients pregnant lactate plan become pregnant prior completion study . Patients consume investigational product 30 day prior transplantation time posttransplantation followup . Patients receive cholestyramine colestipol . Patients one follow enrolment : 1 . History malignancy , chartdocumented cured active malignancy ( exception eradicable nonmetastatic insitu basal cell squamous cell carcinoma ) . 2 . Leukopenia ( white cell count &lt; 2500/cu mm ) . 3 . Anemia ( hemoglobin &lt; 80 g/L ) . 4 . Positive test hepatitis B surface antigen and/or hepatitis C. 5 . Historical positive test human immunodeficiency virus ( HIV ) . 6 . Serum creatinine &gt; 230 umol/l . 7 . Continual elevation AST and/or ALT &gt; = 3X upper limit normal . 8 . Body mass index ( weight kg/height m2 ) &gt; 30 . Undiagnosed diabetes mellitus determine 2 hour ( 2h ) oral glucose tolerance test ( OGTT ) fast glucose test uncontrolled diabetes mellitus screen . In either case , patient may declare long excluded criterion upon establishment control diabetes appropriate medical management . Blood glucose &gt; = 11.1 mmol/L preoperative assessment . Patients significant disease , substance dependency , disability may prevent adherence , understanding , protocol and/or investigator 's instruction .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Treatment Outcome</keyword>
	<keyword>Treatment Effectiveness</keyword>
	<keyword>Anti-rejection therapy</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Antirejection</keyword>
</DOC>